CLINICAL_TRIALS
trial_result
· 2023-08-14
Clinical Trial Update: Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia [Phase 2, Phase 3]
Summary
Phase 2 and Phase 3 trials evaluated MT-5199 for efficacy and safety in tardive dyskinesia. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tanabe Pharma Corporation | Conditions: Tardive Dyskinesia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-08-14